Patients with type 2 diabetes are treated with many drugs other than insulin. In 2014, Medicare paid 58 million claims for noninsulin diabetes drugs. Most of these claims were for agents that have been used for many years: 53% were for metformin, the consensus first-line drug; 30% for ...
Typ-2-Diabetes - die neue Nationale VersorgungsLeitlinie Diabetes 2021 (Teil 1) doi:10.3238/zfa.2021.0269-0274Background Type 2 diabetes is frequently diagnosed in Germany with a prevalence of over 7 %, although there are indications of a declining incidence. The majority ...
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, 52-... Michael,A,Nauck,... - 《Diabetes Care》 被引量: 518发表: 2011年 Effekt von Dapagliflozin bei Typ-2-Diabetikern mit unzureichender Blut...
Combination Therapies of DPP4 Inhibitors and GLP1 Analogues with Insulin in Type 2 Diabetic Patients: A Systematic Review Objective: The use of dipeptidyl-peptidase 4 (DPP4) inhibitors and glucagon like peptide 1 (GLP1) analogues for the treatment of diabetic mellitus (DM) typ... C Rizos,Evang...
Background:In 2002, fixed-dose combination therapy (FDCT) with rosiglitazone maleate plus metformin hydrochloride became available for the treatment of typ... DR Vanderpoel,MA Hussein,T Watson-Heidari,... - 《Clinical Therapeutics》 被引量: 130发表: 2004年 Fixed-Dose Combination Antihypertensives ...
In addition, we performed subgroup analyses to assess a difference in the effect depending on two modes of combination based on whether the subjects (i) used the SGLT2 inhibitor and DPP4 inhibitor simultaneously; or (ii) used the SGLT2 inhibitor sequentially after using the DPP4 inhibitor first...
Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. To determine whether, over daytime, one or several hyperglycemic excursions exist that can be general failures in the glycemic control of patients with typ... L Monnier...
Nichtmenschliches transgenes tier als modell für typ-2-diabetesdoi:EP1743523 A1The invention provides a non-human transgenic animal as a model of type 2 diabetes manifesting a symptom of type 2 diabetes by excessive expression of the active SREBP-2 protein in pancreatic 尾-cells by introducing...
DIABETES:Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetesOBJECTIVERESEARCH DESIGN AND METHODStype diabetesRESULTSplasma RBP concentrationCONCLUSIONSksparksnu.ac.kr...
Translational Neurodegeneration (2023) Typ-1-Diabetes – neue Aspekte in Therapie und Technologie 2023 Thomas Schimmel Thomas Ebert Die Diabetologie (2023)Download PDF Associated content Collection Glucagon: celebrating 100 years Collection Child and Adolescent Health 2022 Sections Figures References...